| Juzar Ali, MD,FRCP, FCCP(C) | |
|
1450 Poydras St, New Orleans, LA 70112-6010 | |
| (504) 903-1932 | |
| (504) 903-2023 |
| Full Name | Juzar Ali |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 51 Years |
| Location | 1450 Poydras St, New Orleans, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508887522 | NPI | - | NPPES |
| 04086534 | Medicaid | MS | |
| 1922528 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 4166R (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Medical Center New Orleans | New orleans, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Louisiana Department Of Health - Office Of Public Health | 5890700694 | 24 |
News Archive
Two new studies developed algorithms that can identify patients who are at risk of acquiring HIV and may benefit from preventive care. Both studies appear in the July 5 issue of The Lancet HIV.
The economic cost to the NHS of vomiting and nausea during pregnancy is over £60 million, higher than previously thought, according to new estimates by the University of Warwick.
Pfizer and Wyeth announced today that Pfizer has completed its acquisition of Wyeth following the receipt of regulatory approval from all government authorities required by the merger agreement and approval by Wyeth shareholders.
Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).
› Verified 2 days ago
| Entity Name | Louisiana State University School Of Medicine In New Orleans Faculty G |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477582526 PECOS PAC ID: 0244136448 Enrollment ID: O20031209000661 |
News Archive
Two new studies developed algorithms that can identify patients who are at risk of acquiring HIV and may benefit from preventive care. Both studies appear in the July 5 issue of The Lancet HIV.
The economic cost to the NHS of vomiting and nausea during pregnancy is over £60 million, higher than previously thought, according to new estimates by the University of Warwick.
Pfizer and Wyeth announced today that Pfizer has completed its acquisition of Wyeth following the receipt of regulatory approval from all government authorities required by the merger agreement and approval by Wyeth shareholders.
Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).
› Verified 2 days ago
| Entity Name | Louisiana Department Of Health - Office Of Public Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144372343 PECOS PAC ID: 5890700694 Enrollment ID: O20140815000393 |
News Archive
Two new studies developed algorithms that can identify patients who are at risk of acquiring HIV and may benefit from preventive care. Both studies appear in the July 5 issue of The Lancet HIV.
The economic cost to the NHS of vomiting and nausea during pregnancy is over £60 million, higher than previously thought, according to new estimates by the University of Warwick.
Pfizer and Wyeth announced today that Pfizer has completed its acquisition of Wyeth following the receipt of regulatory approval from all government authorities required by the merger agreement and approval by Wyeth shareholders.
Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Juzar Ali, MD,FRCP, FCCP(C) 1340 Poydras St, Suite 1640, New Orleans, LA 70112-1221 Ph: (504) 412-1835 | Juzar Ali, MD,FRCP, FCCP(C) 1450 Poydras St, New Orleans, LA 70112-6010 Ph: (504) 903-1932 |
News Archive
Two new studies developed algorithms that can identify patients who are at risk of acquiring HIV and may benefit from preventive care. Both studies appear in the July 5 issue of The Lancet HIV.
The economic cost to the NHS of vomiting and nausea during pregnancy is over £60 million, higher than previously thought, according to new estimates by the University of Warwick.
Pfizer and Wyeth announced today that Pfizer has completed its acquisition of Wyeth following the receipt of regulatory approval from all government authorities required by the merger agreement and approval by Wyeth shareholders.
Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).
› Verified 2 days ago
Leigh Victoria Deshotels, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1430 Tulane Ave # Sl50, New Orleans, LA 70112 Phone: -- | |
Dr. James Desporte Lilly, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2820 Napoleon Ave, Suite 720, New Orleans, LA 70115 Phone: 504-896-8670 Fax: 504-896-8699 | |
Carmen Gladys Espinoza, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1542 Tulane Ave, New Orleans, LA 70112 Phone: 504-903-1301 | |
Jose Rodrigo Restrepo, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: Department Of Radiology, 1542 Tulane Ave, Box T2-2, New Orleans, LA 70112 Phone: 504-568-4646 | |
Jorge Alan Martinez, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2021 Perdido St, New Orleans, LA 70112 Phone: 504-903-3000 | |
Dr. Princess Eronmwon Dennar, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1430 Tulane Ave, Sl-16, New Orleans, LA 70112 Phone: 504-988-7518 Fax: 504-988-8252 | |
Eric Edward Holt I, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4747 Earhart Blvd Ste. J, New Orleans, LA 70125 Phone: 504-592-9818 Fax: 504-522-2248 |